Crescent Biopharma (CBIO) closed at $13.06 on November 3, 2026, up 1.2% from the previous close, on volume of 149,017 shares (30-day average 321,474).
Data as of November 3, 2026.
Crescent Biopharma Announces Grants of Inducement Awards
Globe Newswire (Tue, 3-Nov 4:15 PM ET)
TipRanks (Mon, 2-Nov 9:20 AM ET)
Crescent Biopharma to Present at November Investor Conferences
Globe Newswire (Mon, 2-Nov 7:30 AM ET)
Globe Newswire (Thu, 15-Oct 4:15 PM ET)
Globe Newswire (Mon, 5-Oct 7:30 AM ET)
Crescent Biopharma to Present at September Investor Conferences
Globe Newswire (Thu, 3-Sep 7:30 AM ET)
Market Chameleon (Wed, 15-Jul 4:56 AM ET)
Crescent Biopharma's $185 Million Partnership Boosts Pipeline for Solid Tumor Therapies
Market Chameleon (Thu, 4-Dec 2:05 AM ET)
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Crescent Biopharma trades on the NASDAQ stock market under the symbol CBIO.
As of November 4, 2026, CBIO stock price climbed to $13.53 with 49,263 million shares trading.
CBIO has a beta of 1.59, meaning it tends to be more sensitive to market movements. CBIO has a correlation of 0.04 to the broad based SPY ETF.
CBIO has a market cap of $502.56 million. This is considered a Small Cap stock.
Last quarter Crescent Biopharma reported $0 in Revenue and -$.74 earnings per share. This fell short of revenue expectation by $-357,140 and missed earnings estimates by -$.07.
The top ETF exchange traded funds that CBIO belongs to (by Net Assets): VTI, IWM, VXF, XBI, IWO.
CBIO has underperformed the market in the last year with a return of +9.6%, while the SPY ETF gained +13.5%. In the last 3 month period, CBIO fell short of the market, returning -9.0%, while SPY returned +1.6%. However, in the most recent 2 weeks CBIO has outperformed the stock market by returning +3.5%, while SPY returned -0.1%.
CBIO support price is $12.32 and resistance is $13.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CBIO shares will trade within this expected range on the day.
